Publication | Open Access

Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)

De Novo EgfrMedicinePathologyCancer TreatmentCancer GeneticsClinical OutcomeOncologyRadiation OncologyLung Cancer